this thing is capped at $4.5m with significant success in their first batch of treated patients. Its been a long time since i have seen a small bio stock have success with human trials. Have a read of the announcement if you like, it might be a very interesting ride over time for a company like this. The first 10 patients all scored 100%. dyor.
this thing is capped at $4.5m with significant success in their...
Add to My Watchlist
What is My Watchlist?